Zoetis Inc. reported its fourth quarter and full year 2024 financial results, revealing a revenue of $2.3 billion, marking a 5% increase year-over-year. The company's net income reached $581 million, translating to $1.29 per diluted share, which reflects an 11% and 13% increase, respectively, on a reported basis. Adjusted earnings per share (EPS) were reported at $1.40. The growth was primarily driven by a 9% year-over-year operational increase in companion animal products, particularly from its offerings such as Simparica Trio, Apoquel, and Cytopoint. Despite these results being in line with estimates, Zoetis's stock experienced a pre-market decline of 7.9%.